1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
- Aronsson-Kurttila, W, et al.
(författare)
-
Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation
- 2018
-
Ingår i: Acta haematologica. - : S. Karger AG. - 1421-9662 .- 0001-5792. ; 139:2, s. 106-114
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background/Aims:</i></b> Hemorrhagic cystitis (HC) is a serious complication after hematopoietic stem cell transplantation (HSCT). Stromal cells have been tested as therapy for HC. Decidua stromal cells (DSCs) protect the fetus from the mother's immune system. <b><i>Methods:</i></b> Eleven patients with HC of grades 3-4 were treated with DSCs after HSCT. The median age was 33 years (range 8-50), and the median dose of DSCs was 1.5 × 10<sup>6</sup>/kg (range 0.7-2.5). The patients were given 1 dose (1-4). <b><i>Results:</i></b> In 5 patients, HC disappeared within 5 days after DSC infusion. Patients who received DSCs within 3 days after the start of HC had a duration of HC of 5 days and a shorter duration of pain than patients who were given DSCs later (<i>p</i> = 0.02). Three patients received DSCs prepared in albumin instead of AB-plasma and tended to have a shorter duration of pain (<i>p</i> = 0.07). There was no infusion toxicity. Adverse events were those often seen after HSCT. Nine of the 11 patients (82%) were alive 1 year after HSCT. <b><i>Conclusions:</i></b> Based on this pilot study, we started a randomized, placebo-controlled double-blind study using 2 doses of 1 × 10<sup>6</sup> DSCs/kg suspended in albumin for treatment of early HC.
|
|
10. |
|
|